Table 7.
Incremental cost-effectiveness ratios—cost per seizure avoided
| Cost (£) | Seizures | Incremental cost (£) |
Incremental seizures avoided |
Incremental cost-effectiveness ratio (£/seizure avoided) |
|
|---|---|---|---|---|---|
| Comparison excluding oxcarbazepine | |||||
| Carbamazepine | 1266 | 52·6 | .. | .. | .. |
| Topiramate | 2008 | 63·1 | 742 | −10·5 | Dominated |
| Lamotrigine | 2134 | 41·7 | 126 | 21·4 | 80 |
| Gabapentin | 2494 | 69·8 | 360 | −28·1 | Dominated |
| Comparison including oxcarbazepine | |||||
| Carbamazepine | 1151 | 50·9 | .. | .. | .. |
| Oxcarbazepine | 1815 | 32·0 | 664 | 18·9 | 35 |
| Lamotrigine | 1946 | 50·9 | 131 | −18·9 | Dominated |
| Topiramate | 2059 | 59·4 | 113 | −8·5 | Dominated |
| Gabapentin | 2594 | 85·3 | 535 | −25·9 | Dominated |